<DOC>
	<DOCNO>NCT02113293</DOCNO>
	<brief_summary>This study intend investigate tolerability safety Cyclosporine A contain CyclASol® eye drop compare Placebo ( vehicle ) cohort healthy volunteer . Subjects randomly assign dose CyclASol® eye drop Placebo ( vehicle ) first part ( first period ) study , switch alternative dose second part ( second period ) study . An ophthalmological assessment eye perform , questionnaire issue begin dose . Additionally physical examination , safety laboratory ECGs perform , blood sample analyze Cyclosporine A Placebo ( vehicle ) .</brief_summary>
	<brief_title>CyclASol® Phase 1 Study</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Healthy male female subject age 18 45 year Nonsmoker , least three month prior first dose trial medication BMI 18.5 29.9 ( kg/m2 ) Corneal/Conjunctival stain Oxford grade = 0° Schirmer I 10 mm/5min Tear Film BreakUp Time ( TFBUT ) equal 10 Intraocular pressure 10 20 mmHg Normal funduscopy Subject give voluntary write informed consent participate study language willing comply protocol History clinically relevant allergy ( except untreated , asymptomatic , seasonal allergy time dose ) History dry eye disease , ocular surgery , corneal disease Known hypersensitivity drug substance Limbal stem cell deficiency Cicatricial pemphigoid Glaucoma know steroid response intraocular pressure Ocular allergy incompatibility Ciclosporin semifluorinated alkane Punctual occlusion Corrected vision glass less 0.7 one eye Contact lens wear 3 week plan first drug administration and/or study Acute infection ocular surface ( bacterial , viral , fungal ... ) Acute trauma ocular surface No acceptable method birth control Pregnancy breastfeed period ( female ) Use drug whatsoever ( include vitamin herbal ) fourteen ( 14 ) day prior plan first drug administration ( exclude contraceptive woman single use paracetamol ibuprofen ) Topical systemic therapy steroid , Ciclosporin , nonsteroidal anti inflammatory drug , tetracycline immunomodulatory substance within last 90 day prior plan first drug administration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>phase I study</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>CyclASol®</keyword>
	<keyword>eye drop</keyword>
</DOC>